We are dedicated to developing an innovative pipeline of NKT cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. #GRI #IPF #FibroticDisease #IdiopathicPulmonaryFibrosis
GRI Bio, Inc.
生物技术
San Diego，CA 649 位关注者
Advancing Pipeline of Natural Killer T Cell Modulators for the Treatment of Inflammatory and Fibrotic Diseases.
关于我们
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
- 网站
-
https://www.gribio.com
GRI Bio, Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- San Diego，CA
- 类型
- 上市公司
- 创立
- 2009
- 领域
- NKT cells、inflammation、hepatitis、autoimmunity、alcoholic liver disease、liver disease、fibrosis、505(b)(2)、Natural Killer T和drug development
地点
-
主要
获取路线
8954 Rio San Diego Drive
Suite 102
US，CA，San Diego，92108
GRI Bio, Inc.员工
动态
-
GRI Bio Participates in a Virtual Investor CEO Connect Segment https://bit.ly/4iNR0dm #GRI #IPF #FibroticDisease #IdiopathicPulmonaryFibrosis
-
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) https://bit.ly/4hfh3sE #GRI #IPF #FibroticDisease #IdiopathicPulmonaryFibrosis
-
We have a library of publications showcasing our promising data in developing potential treatments for fibrotic diseases. Check it out//bit.ly/3OhuOf8 #GRI #IPF #FibroticDisease #IdiopathicPulmonaryFibrosis
-
-
We’re halfway through \#PRWeek2025! Let’s keep advocating for better resources and stronger support systems for those affected. https://bit.ly/3CN2ONw \#GRI \#PulmonaryRehabilitation\#LungDisease @[ American Association of Cardiovascular and Pulmonary Rehabilitation \(AACVPR\)](urn:li:organization:53473404)
-
-
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule https://bit.ly/43zT1oU #GRI #FibroticDisease #IdiopathicPulmonaryFibrosis
-
\#PRWeek2025 kicks off today! This week highlights the role of \#PulmonaryRehabilitation in improving the lives of those with lung disease. We honor rehabilitation therapists and emphasize the need for more research and support. https://bit.ly/3CN2ONw \#GRI \#LungDisease @[ American Association of Cardiovascular and Pulmonary Rehabilitation \(AACVPR\)](urn:li:organization:53473404)
-
-
#InCaseYouMissedIt: We participated in the #VirtualInvestor Top 5 for '25 conference. Access our segment on-demand here: https://lnkd.in/ey4fBbRu #GRI #FibroticDisease #IdiopathicPulmonaryFibrosis
-
March is #AutoimmuneAwarenessMonth! Let’s raise awareness, support research and bring hope to those affected by autoimmune diseases. Learn more: https://bit.ly/4bHqzmw #GRI Autoimmune Association #IPF #FibroticDisease #IdiopathicPulmonaryFibrosis
-
-
Systemic Lupus Erythematosus is an autoimmune disease in which the immune system attacks its own tissue and organs, and makes up around 70% of all lupus cases. Current treatments are limited, but we are exploring new options to make a difference. https://bit.ly/3Lk8csv #GRI #FibroticDisease #SLE
-